GE HealthCare started at buy at Mizuho on demand for imaging procedures
JaysonPhotography


Mizuho has initiated GE HealthCare Technologies (NASDAQ:GEHC) with a buy rating, saying that there are several ongoing factors that will lead to an increase in radiology and imaging services.
The firm has a price target of $90 (~27% upside based on Thursday's close).

Analyst Anthony Petrone said that a Mizuho radiology survey indicated there is pent-up demand for U.S. hospital imaging capacity and hospital surveys indicate a return to double-digit growth in imaging procedures.
Also, the EU has an aging imaging system that needs upgrading. He added that the approval of Biogen's Alzheimer's treatment Leqembi (lecanemab) could lead to a surge in demand for MRI brain scans.
Petrone noted that the Leqembi scans could lead to up to $1B in MRI capital demand potential.
The radiology survey found that radiology volumes are expected to increase 6%-8% this year. Also, 50% of sites plan to acquire multiple systems, especially CT and MRI.
Read why Seeking Alpha contributor Daniel Jones, who has a strong buy rating, calls GE HealthCare "significantly undervalued."